Cannabis based drug is licensed for spasticity in patients with MS

BMJ 2010; 340 doi: (Published 22 June 2010) Cite this as: BMJ 2010;340:c3363
  1. Zosia Kmietowicz
  1. 1London

    The first drug derived from the cannabis plant to be granted a licence by UK authorities has been made available for relief of spasticity in patients with multiple sclerosis.

    Sativex oromucosal spray, from Bayer Schering Pharma UK, is indicated as an add-on treatment for patients with moderate to severe spasticity from multiple sclerosis who do not respond adequately to other antispasticity drugs and who show a clinically significant response during an initial trial of the treatment. It contains two cannabinoids in equal quantities: cannabidiol and delta-9-tetrahydrocannabinol.

    Spasticity is a common symptom in people with multiple …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to to receive unlimited access to all content on for 14 days.
    Sign up for a free trial